Jun Luo1, Liting Feng1, Qing Zhou2, Qin Chen3, Jinping Liu4, Chihua Wu4, Jing Luo4, Jie Chen4, Hao Wu1, Wanyue Deng1. 1. Department of Ultrasound, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W.Sec 2,1st Ring Rd, 610072, Chengdu, China. 2. Department of Ultrasound, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W.Sec 2,1st Ring Rd, 610072, Chengdu, China. uszhouqing@hotmail.com. 3. Department of Ultrasound, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 32# W.Sec 2,1st Ring Rd, 610072, Chengdu, China. 1718686103@qq.com. 4. Department of Breast Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, 610072, Chengdu, China.
Abstract
BACKGROUND: This study aimed to explore the sentinel lymph node (SLN) identification rate in breast cancer by subcutaneous and intradermal injection of ultrasound contrast agent in the mammary areola region, compared to the results achieved with methylene blue (MB). METHODS: A total of 390 breast cancer patients with planned sentinel lymph node biopsy from our breast surgery department from July 2017 to February 2019 were enrolled. All patients were subjected to preoperative contrast-enhanced ultrasound (CEUS), that involved an intracutaneous injection of 1 mL ultrasonic contrast agent (UCA) at 3 and 6 o 'clock, as well as a subcutaneous injection of 1 mL UCA at 9 and 12 o'clock. The enhanced lymph nodes along the enhanced lymphatic vessels from the mammary areola were traced. The number of enhanced lymph nodes were recorded, and an ultrasound-guided injection of 1:10 diluted carbon nanoparticles were used to mark all first site enhanced lymph nodes (i.e., SLNs). An intraoperative dye method (MB) was used to track the SLNs and the results were compared with the CEUS findings. RESULTS: Among the 390 cases of breast cancer, enhanced SLNs were observed in 373 patients after an injection of UCA with an identification rate of 95.64 % (373/390), compared to the identification rate of 92.05 % (359/390) using the intraoperative MB. The difference between the two methods was statistically significant (P = 0.016). And among the 390 patients, a total of 808 enhanced lymph nodes were traced by preoperative CEUS, with a median of 2 (1,3). A total of 971 blue-stained lymph nodes were traced using the intraoperative MB, with a median of 2 (2,3), indicating a statistically significant difference (p < 0.001). CONCLUSIONS: Intradermal and subcutaneous injections of UCA in the mammary areola region may have clinical application value for the identification and localization of SLNs in breast cancer patients. The identification rate is higher than that of blue dye method, which can be used as a new tracer of sentinel lymph node biopsy and complement other staining methods to improve the success rate.
BACKGROUND: This study aimed to explore the sentinel lymph node (SLN) identification rate in breast cancer by subcutaneous and intradermal injection of ultrasound contrast agent in the mammary areola region, compared to the results achieved with methylene blue (MB). METHODS: A total of 390 breast cancerpatients with planned sentinel lymph node biopsy from our breast surgery department from July 2017 to February 2019 were enrolled. All patients were subjected to preoperative contrast-enhanced ultrasound (CEUS), that involved an intracutaneous injection of 1 mL ultrasonic contrast agent (UCA) at 3 and 6 o 'clock, as well as a subcutaneous injection of 1 mL UCA at 9 and 12 o'clock. The enhanced lymph nodes along the enhanced lymphatic vessels from the mammary areola were traced. The number of enhanced lymph nodes were recorded, and an ultrasound-guided injection of 1:10 diluted carbon nanoparticles were used to mark all first site enhanced lymph nodes (i.e., SLNs). An intraoperative dye method (MB) was used to track the SLNs and the results were compared with the CEUS findings. RESULTS: Among the 390 cases of breast cancer, enhanced SLNs were observed in 373 patients after an injection of UCA with an identification rate of 95.64 % (373/390), compared to the identification rate of 92.05 % (359/390) using the intraoperative MB. The difference between the two methods was statistically significant (P = 0.016). And among the 390 patients, a total of 808 enhanced lymph nodes were traced by preoperative CEUS, with a median of 2 (1,3). A total of 971 blue-stained lymph nodes were traced using the intraoperative MB, with a median of 2 (2,3), indicating a statistically significant difference (p < 0.001). CONCLUSIONS: Intradermal and subcutaneous injections of UCA in the mammary areola region may have clinical application value for the identification and localization of SLNs in breast cancerpatients. The identification rate is higher than that of blue dye method, which can be used as a new tracer of sentinel lymph node biopsy and complement other staining methods to improve the success rate.
Entities:
Keywords:
Breast cancer; Contrast‐enhanced ultrasound (CEUS); Sentinel lymph node (SLN)
Authors: Armando E Giuliano; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Monica Morrow; Karla Ballman Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Joseph P Costantino; Takamaru Ashikaga; Donald L Weaver; Eleftherios P Mamounas; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh Mc Scarth; Norman Wolmark Journal: Lancet Oncol Date: 2010-10 Impact factor: 41.316
Authors: Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow Journal: JAMA Date: 2011-02-09 Impact factor: 56.272
Authors: Fei Xie; Dongjie Zhang; Lin Cheng; Lei Yu; Li Yang; Fuzhong Tong; Hongjun Liu; Shu Wang; Shan Wang Journal: World J Surg Oncol Date: 2015-11-19 Impact factor: 2.754